腹膜转移：从黯淡前景到令人鼓舞的现状及充满希望的未来的演变
Peritoneal Metastases: Evolution from a Dark Horizon to an Encouraging Present and a Promising Future.
作者信息
Diez-Alonso Manuel, San-Juan Alberto, Ortega Miguel Angel, Gutiérrez-Calvo Alberto
机构信息
General Surgery Service, University Hospital Príncipe de Asturias, 28820 Alcalá de Henares, Spain.
Medical Oncology Service, University Hospital Príncipe de Asturias, 28820 Alcalá de Henares, Spain.
出版信息
J Clin Med. 2023 Dec 6;12(24):7536. doi: 10.3390/jcm12247536.
Abstract
Peritoneal metastasis (PM) is the primary pattern of metastasis for primary tumours of the appendix, ovary, and peritoneal mesothelioma [...].
摘要
腹膜转移（PM）是阑尾、卵巢和腹膜间皮瘤等原发性肿瘤转移的主要模式[……]
相似文献
1
Peritoneal Metastases: Evolution from a Dark Horizon to an Encouraging Present and a Promising Future.腹膜转移：从黯淡前景到令人鼓舞的现状及充满希望的未来的演变
J Clin Med. 2023 Dec 6;12(24):7536. doi: 10.3390/jcm12247536.
2
Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases.高热术中腹腔化疗在腹腔转移瘤治疗中的作用。
Eur J Cancer. 2014 Jan;50(2):332-40. doi: 10.1016/j.ejca.2013.09.024. Epub 2013 Oct 21.
3
Patients with extensive regional lymph node involvement (pN2) following potentially curative surgery for colorectal cancer are at increased risk for developing peritoneal metastases: a retrospective single-institution study.对于接受潜在治愈性手术治疗的结直肠癌患者，如果存在广泛的区域性淋巴结受累（pN2），则发生腹膜转移的风险增加：一项回顾性单机构研究。
Colorectal Dis. 2019 Mar;21(3):287-296. doi: 10.1111/codi.14481. Epub 2018 Dec 21.
4
Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate.中国腹膜转移瘤的临床流行病学：基于患病率构建专业腹膜转移瘤治疗中心
Eur J Surg Oncol. 2023 Jan;49(1):173-178. doi: 10.1016/j.ejso.2022.08.023. Epub 2022 Aug 28.
5
Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI).完整的细胞减灭术联合 HIPEC 治疗源自罕见部位的腹膜转移癌：腹膜表面肿瘤国际协会（PSOGI）的全球分析结果。
Int J Hyperthermia. 2017 Aug;33(5):520-527. doi: 10.1080/02656736.2017.1301576.
6
Brain Metastases With Malignant Peritoneal Mesothelioma: Never Reported Before.恶性腹膜间皮瘤伴脑转移：此前从未有过报道。
Cureus. 2023 Aug 19;15(8):e43744. doi: 10.7759/cureus.43744. eCollection 2023 Aug.
7
Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases.错配修复缺陷转移性结直肠癌患者的生存情况无论是否合并腹膜转移均较差。
Ann Surg Oncol. 2020 Dec;27(13):5074-5083. doi: 10.1245/s10434-020-08733-x. Epub 2020 Jun 24.
8
[Pathologic and anatomic evidence of peritoneal metastases].[腹膜转移的病理及解剖学证据]
Chirurg. 2007 Dec;78(12):1085-6, 1088-90. doi: 10.1007/s00104-007-1427-0.
9
The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.印度在细胞减灭术和腹腔热灌注化疗治疗腹膜转移瘤方面的初步经验。
Indian J Surg Oncol. 2016 Jun;7(2):160-5. doi: 10.1007/s13193-016-0500-x. Epub 2016 Feb 2.
10
The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future.腹膜转移的当代管理：从治疗无效的冷酷过去走向温暖的现在和光明的未来的历程。
CA Cancer J Clin. 2023 Jan;73(1):49-71. doi: 10.3322/caac.21749. Epub 2022 Aug 15.
引用本文的文献
1
Assessment of Intraoperative Scoring Systems for Predicting Cytoreduction Outcome in Peritoneal Metastatic Disease: A Systematic Review and Meta-analysis.评估预测腹膜转移疾病细胞减灭术结局的术中评分系统：系统评价和荟萃分析。
Ann Surg Oncol. 2024 Oct;31(10):7165-7183. doi: 10.1245/s10434-024-15629-7. Epub 2024 Jun 25.
本文引用的文献
1
Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial.局部进展期结肠癌术中腹腔热灌注化疗的疗效和安全性：一项 3 期随机临床试验。
JAMA Surg. 2023 Jul 1;158(7):683-691. doi: 10.1001/jamasurg.2023.0662.
2
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利、奥拉帕利和贝伐单抗作为新诊断晚期卵巢癌患者维持治疗的网状Meta分析及非锚定人群校正间接治疗比较的可行性研究
Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285.
3
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗联合化疗对比安慰剂联合化疗用于治疗人表皮生长因子受体 2（HER2）阴性、未经治疗、不可切除的晚期或复发性胃或胃食管结合部腺癌患者（ATTRACTION-4）：一项随机、多中心、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11.
4
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.细胞减灭术联合腹腔热灌注化疗与单纯细胞减灭术治疗结直肠腹膜转移瘤（PRODIGE 7）：一项多中心、随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18.
5
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.二期手术加腹腔内热灌注化疗与监测在有发生结直肠腹膜转移高危患者中的对比（PROPHYLOCHIP-PRODIGE 15）：一项随机、3 期研究。
Lancet Oncol. 2020 Sep;21(9):1147-1154. doi: 10.1016/S1470-2045(20)30322-3. Epub 2020 Jul 24.
6
The forefront of ovarian cancer therapy: update on PARP inhibitors.卵巢癌治疗的前沿：PARP 抑制剂的最新进展。
Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20.
7
Colorectal cancer peritoneal metastases: Biology, treatment and next steps.结直肠癌腹膜转移：生物学、治疗和下一步。
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):675-683. doi: 10.1016/j.ejso.2019.10.035. Epub 2019 Oct 31.
8
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.局部晚期结肠癌患者的辅助腹腔内热化疗（COLOPEC）：一项多中心、开放标签、随机试验。
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770. doi: 10.1016/S2468-1253(19)30239-0. Epub 2019 Jul 29.
9
Colorectal peritoneal metastases: Optimal management review.结直肠腹膜转移：最佳管理综述。
World J Gastroenterol. 2019 Jul 21;25(27):3484-3502. doi: 10.3748/wjg.v25.i27.3484.
10
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).围手术期全身治疗联合细胞减灭术和 HIPEC 对比单纯 HIPEC upfront 细胞减灭术治疗孤立可切除结直肠腹膜转移瘤：一项多中心、开放标签、平行组、Ⅱ-Ⅲ 期、随机、优效性研究（CAIRO6）方案。
BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.
Zotero 插件